Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 (ianalumab) in pemphigus vulgaris
2013-001217-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in pemphigus vulgaris (PV) comparing VAY736 (ianalumab) single IV dose with Placebo IV (2 arms). Primary endpoint: Change in Pemphigus Disease Area Index (PDAI) from baseline to 12 weeks. Started Oct 2013; status: completed.
02
Drugs
ianalumab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2013-001217-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001217-33.